Journal articleClin Cancer Res2020
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
- Journal
- Clin Cancer Res
- Published
- 9 April 2020
- Citations
- 141
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsGVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab NCT02243371↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.
Grants 4
- Cancer Prevention and Control Program P30CA006973↗
- Core 2: Biospecimen/Pathology Core P50CA062924↗
- Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial R01CA197296↗
- Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗